Literature DB >> 22112811

Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes.

A A Verrijn Stuart1, H S Schipper, I Tasdelen, D A Egan, B J Prakken, E Kalkhoven, W de Jager.   

Abstract

CONTEXT: Type 1 diabetes (T1D) is considered a proinflammatory condition. Adipose tissue involvement seems evident because adiponectin levels correlate with disease remission and administration of leptin suppresses the low-grade systemic inflammation in mice with T1D. Whether adipose tissue involvement in T1D already occurs at a young age is yet unknown.
OBJECTIVE: The aim was to explore the extent of adipokine alterations in pediatric T1D and gain more insight into the mechanisms underlying the involvement of adipose tissue. DESIGN AND PARTICIPANTS: First, plasma adipokine profiling (24 adipokines) of 20 children with onset T1D, 20 children with long-standing T1D, and 17 healthy controls was performed using a recently developed and validated multiplex immunoassay. Second, the effects of diabetic plasma factors on preadipocyte proliferation and differentiation were studied in vitro.
RESULTS: In children with onset and long-standing T1D, plasma adipokine profiling showed increased levels of various adipokines acting at the crossroads of adipose tissue function and inflammation, including CCL2/monocyte chemoattractant protein-1 and the novel adipokines cathepsin S, chemerin, and tissue inhibitor of metalloproteinase-1 (P < 0.05). Furthermore, onset and long-standing diabetic plasma significantly induced preadipocyte proliferation and adipocyte differentiation in vitro (P < 0.05). Two candidate plasma factors, glucose and the saturated fatty acid palmitic acid, did not affect proliferation or adipocyte differentiation in vitro but were found to increase CCL2 (monocyte chemoattractant protein-1) secretion by adipocytes.
CONCLUSIONS: The adipogenic effects of diabetic plasma in vitro and the altered adipokine levels in vivo suggest adipose tissue involvement in the low-grade inflammation associated with T1D, already in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112811     DOI: 10.1210/jc.2011-1858

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Adipose tissue, hormones, and treatment of type 1 diabetes.

Authors:  Subhadra C Gunawardana
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

2.  Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes.

Authors:  H S Schipper; R Nuboer; S Prop; H J van den Ham; F K de Boer; Ç Kesmir; I M H Mombers; K A van Bekkum; J Woudstra; J H Kieft; I E Hoefer; W de Jager; B Prakken; M van Summeren; E Kalkhoven
Journal:  Diabetologia       Date:  2012-07-18       Impact factor: 10.122

Review 3.  Benefits of healthy adipose tissue in the treatment of diabetes.

Authors:  Subhadra C Gunawardana
Journal:  World J Diabetes       Date:  2014-08-15

Review 4.  Chemerin: a potential endocrine link between obesity and type 2 diabetes.

Authors:  Alexandra A Roman; Sebastian D Parlee; Christopher J Sinal
Journal:  Endocrine       Date:  2012-05-19       Impact factor: 3.633

5.  Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity.

Authors:  M Reyman; A A Verrijn Stuart; M van Summeren; M Rakhshandehroo; R Nuboer; F K de Boer; H J van den Ham; E Kalkhoven; B Prakken; H S Schipper
Journal:  Int J Obes (Lond)       Date:  2013-05-20       Impact factor: 5.095

6.  Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes.

Authors:  M J Redondo; L M Rodriguez; M W Haymond; C S Hampe; E O Smith; A Balasubramanyam; S Devaraj
Journal:  Pediatr Diabetes       Date:  2014-06-30       Impact factor: 4.866

7.  Metabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA).

Authors:  Marta Ugarte; Marie Brown; Katherine A Hollywood; Garth J Cooper; Paul N Bishop; Warwick B Dunn
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

8.  Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes.

Authors:  Alireza Esteghamati; Mehrnaz Ghasemiesfe; Mostafa Mousavizadeh; Sina Noshad; Manouchehr Nakhjavani
Journal:  J Diabetes Investig       Date:  2013-10-22       Impact factor: 4.232

9.  Therapeutic value of brown adipose tissue: Correcting metabolic disease through generating healthy fat.

Authors:  Subhadra C Gunawardana
Journal:  Adipocyte       Date:  2012-10-01       Impact factor: 4.534

10.  3T3-L1 preadipocytes exhibit heightened monocyte-chemoattractant protein-1 response to acute fatty acid exposure.

Authors:  Aimee L Dordevic; Nicky Konstantopoulos; David Cameron-Smith
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.